title: Effects of somatostatin analogues on human sphincter of Oddi pressure.
abstract: BACKGROUND
  Somatostatin, a neuropeptide and hormone, exists in the biliary tract of several species. The effects of somatostatin and its analogues on the sphincter of Oddi motility have been controversial. The aim of this study was to observe the action of stilamin and sandostatin on the sphincter of Oddi via choledochofiberscope manometry.
  
  
  METHODS
  Twenty patients who had had "T" duct after cholecystectomy and choledochotomy were divided into 2 groups randomly: stilamin and sandostatin. They were subjected to manometry via a choledochofiberscope through the "T" duct tract. The following data recorded included duodenal pressure (DP), sphincter of Oddi basal pressure (SOBP), sphincter of Oddi contractive amplitude (SOCA), frequency of the sphincter of Oddi (SOF), duration of the sphincter of Oddi, and the common bile duct pressure (CBDP).
  
  
  RESULTS
  After intravenous administration of stilamin at a dose of 250 microg/h, the mean SOCA increased from 89.18(26.50) to 128.57(54.21) mmHg (P<0.05). After the administration of stilamin at a dose of 500 microg/h the mean SOCA declined to 92.18(42.81) mmHg (P<0.05), and mean SOBP declined from 17.63(13.36) to 8.16(4.01) mmHg (P<0.05). Although SOF had declined from 9.25(2.45) to 7.46(1.52) n/min, it was not significantly influenced. After intravenous administration of sandostatin at a dose of 100 microg, the mean CBDP increased obviously.
  
  
  CONCLUSIONS
  Intravenous administration of stilamin at a dose of 250 microg/h stimulates the motility of the sphincter of Oddi whereas the injection of stilamin at a dose of 500 microg/h inhibits its motility. Intravenous injection of sandostatin of 100 mug has no effect on the sphincter of Oddi.
authors.affiliation: Department of General Surgery, Second Affiliated Hospital, China Medical University, Shenyang 110004, China. wushuodong@hotmail.com
authors.forename: Shuo-Dong
authors.initials: SD
authors.lastname: Wu
authors.forename: Zhen-Hai
authors.initials: ZH
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Kong
authors.forename: Yan-Jun
authors.initials: YJ
authors.lastname: Li
authors.forename: Jun-Zhe
authors.initials: JZ
authors.lastname: Jin
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Dong-Yan
authors.initials: DY
authors.lastname: Li
authors.forename: Min-Fei
authors.initials: MF
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D002763:Cholecystectomy / Q000379:methods; D042883:Choledocholithiasis / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008365:Manometry; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D011184:Postoperative Period; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013004:Somatostatin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors*; D009803:Sphincter of Oddi / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D013004:Somatostatin; D015282:Octreotide